AdventHealthMD
A recent study, called FLOW, showed Ozempic had dramatic results in slowing chronic kidney disease progression in participants with Type 2 diabetes.
In the presence of local and national dignitaries, students, alumni, and faculty, AdventHealth University inaugurated C. Josef Ghosn, EdD, FACHE, its third president and CEO.
Our website uses cookies. Please review our privacy policy to find out more about the cookies we use. Browsing our website means you accept these terms.